June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Local recurrence of uveal melanoma increases the risk of metastatic disease in patients with abnormal copy number of chromosome 8
Author Affiliations & Notes
  • Mette Bagger
    Opthalmology, Copenhagen University Hospital, Gentofte, Denmark
    Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark
  • Charlotte Alfast Espensen
    Opthalmology, Copenhagen University Hospital, Gentofte, Denmark
  • Morten T Andersen
    Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark
  • Mette Klarskov Andersen
    Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark
  • Steffen Heegaard
    Opthalmology, Copenhagen University Hospital, Gentofte, Denmark
  • Jens F Kiilgaard
    Opthalmology, Copenhagen University Hospital, Gentofte, Denmark
  • Footnotes
    Commercial Relationships   Mette Bagger, None; Charlotte Espensen, None; Morten Andersen, None; Mette Andersen, None; Steffen Heegaard, None; Jens Kiilgaard, None
  • Footnotes
    Support  Fight for Sight, Denmark, The research grant of Rigshospitalet
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3970. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mette Bagger, Charlotte Alfast Espensen, Morten T Andersen, Mette Klarskov Andersen, Steffen Heegaard, Jens F Kiilgaard; Local recurrence of uveal melanoma increases the risk of metastatic disease in patients with abnormal copy number of chromosome 8. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3970.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Local recurrence (LR) has recently been shown to be an important risk factor for metastatic disease in uveal melanoma (UM) independent of tumor size. However, the relationship between adverse chromosomal aberrations and LR is not known. We performed a single center retrospective consecutive cohort study to evaluate if the risk of LR and the risk of metastatic UM in the presence of LR were affected by genetic status of chromosome 8.

Methods : A consecutive cohort of 216 UM patients who underwent eye conserving treatment at Copenhagen University Hospital from 2008 through 2015 was included in the study and followed up until either death or December 2016. Copy number (CN) of chromosome 8 as assessed by Fluorescence in situ hybridization (FISH) and/or Multiplex ligation-dependent probe amplification (MLPA) and secondary treatment (enucleation or brachytherapy) due to LR were registered. The association between LR and CN of chromosome 8 was evaluated with the X2 test. The risk of metastatic disease in relation to LR and genetic status of chromosome 8 was evaluated using Kaplan Meier survival analysis and the log rank test.

Results : Median follow up time was 4.1 years (range 0.07- 8.9, interquartile range: 2.4-6.3). LR was observed in 32 patients (15.0 %) with a median time from primary treatment to LR of 19.8 months (range 3.9- 91.0; interquartile range: 9.4-32.7). Genetic status of chromosome 8 was available in 23 of the LR cases and was normal in 12 cases and abnormal in 11 cases (p=0.93) . There was no increased risk of LR in the presence of abnormal CN of chromosome 8 (relative risk=1.006 (95% CI 0.88-1.15)). We found a tendency (p=0.11) towards decreased survival in patients with LR compared to patients with no LR (UM specific 5-year survival rate of 75.1% (95%CI: 0.59-0.91) vs.85.6% (95% CI: 0.80-0.91) respectively). No patients with LR and normal CN of chromosome 8 developed metastatic disease in the study period.

Conclusions : An association between abnormal CN of chromosome 8 and LR was not found. LR in UM patients seems to increase the risk of metastatic disease in patients with abnormal CN of chromosome 8 while we observed no decreased survival in patients with LR and normal CN of chromosome 8.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×